Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®. (Q30403438)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®. (English)

1 reference

Europe PubMed Central

21 June 2017

0 references

author name string

John Doukas

1

1 reference

Europe PubMed Central

21 June 2017

Jane Morrow

2

1 reference

Europe PubMed Central

21 June 2017

Dawn Bellinger

3

1 reference

Europe PubMed Central

21 June 2017

Thomas Hilgert

4

1 reference

Europe PubMed Central

21 June 2017

Terrie Martin

5

1 reference

Europe PubMed Central

21 June 2017

Doug Jones

6

1 reference

Europe PubMed Central

21 June 2017

Rohit Mahajan

7

1 reference

Europe PubMed Central

21 June 2017

Denis Rusalov

8

1 reference

Europe PubMed Central

21 June 2017

Sean Sullivan

9

1 reference

Europe PubMed Central

21 June 2017

Alain Rolland

10

1 reference

Europe PubMed Central

21 June 2017

language of work or name

0 references

publication date

17 June 2011

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

29

1 reference

Europe PubMed Central

21 June 2017

33

1 reference

Europe PubMed Central

21 June 2017

5443-5452

1 reference

Europe PubMed Central

21 June 2017

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Current progress of DNA vaccine studies in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Cationic lipid-based gene delivery systems: pharmaceutical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Potential DNA vaccine integration into host cell genome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-Inserts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Update on avian influenza A (H5N1) virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.060

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.05.060

1 reference

Europe PubMed Central

21 June 2017

release_qxsy2wopxzhvfainlyjvk557vi

1 reference

https://api.fatcat.wiki/v0/release/qxsy2wopxzhvfainlyjvk557vi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30403438&oldid=1843191630"